Atyr PHARMA (NASDAQ:ATYR) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $35.00 price objective on the stock.

Several other equities analysts also recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a “buy” rating and a $9.00 price objective for the company. Wells Fargo & Company started coverage on Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $16.00 price target on shares of Atyr PHARMA in a research note on Wednesday, August 14th.

Atyr PHARMA Stock Performance

Shares of NASDAQ ATYR opened at $3.32 on Tuesday. The stock’s 50-day simple moving average is $2.14. The company has a quick ratio of 7.63, a current ratio of 7.63 and a debt-to-equity ratio of 0.01. The firm has a market cap of $229.12 million, a price-to-earnings ratio of -3.69 and a beta of 1.21. Atyr PHARMA has a fifty-two week low of $1.08 and a fifty-two week high of $3.68.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. On average, sell-side analysts forecast that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.